Action Kidney Cancer

05/10/2026

A recently published UK study looked at pembrolizumab after surgery (adjuvant pembrolizumab) for clear cell kidney cancer in NHS care.

Pembrolizumab may be offered after surgery to patients with clear cell kidney cancer who have a higher chance of the cancer returning. However, there is still limited information about how often it is used, its side effects and how well it works in everyday care.

This UK study looked at patients taking adjuvant pembrolizumab in the clinic. Researchers examined how treatment decisions were made, what side effects patients had, why treatment was stopped, and how long patients lived without the cancer returning.

Read more on our website here:

A recently published UK study looked at pembrolizumab after surgery (adjuvant pembrolizumab) for clear cell kidney cancer in NHS care. Pembrolizumab may be offered after surgery to patients with clear cell kidney cancer who have a higher chance of the cancer returning. However, there is still limite...

02/10/2026

Thank you to the Specialist Kidney Cancer Centre at the Royal Free Hospital team for raising awareness of kidney cancer today.
The team provided information to the general public on early signs and symptoms of kidney cancer, shared support available and gave people the opportunity to speak to the team.
People attending the information stall were really engaged and keen to talk to the team about early, signs and symptoms of kidney cancer to look out for.

The team also thanked us for proving accurate, useful information and promotional material.

30/09/2026

Because smoking is one of the main risk factors for the development of kidney cancer, Action Kidney Cancer is supporting the NHS campaign, Stoptober.

Stoptober starts tomorrow! You are doing the best thing you can for your health by quitting – and you don’t need to do it alone. There are plenty of ways to get support, but the best way to get started is to get your free Personal Quit Plan.

Visit our website for more information to help you stop smoking:
https://actionkidneycancer.org/stoptober-starts-tomorrow/

30/09/2026

Stereotactic ablative radiotherapy (SABR) may help people with kidney cancer that has not spread. Surgery is the usual treatment, but it may not be suitable for everyone.

SABR is a non-invasive treatment that does not need surgery or a general anaesthetic. It is usually given as 3 to 5 outpatient treatments over 1 to 2 weeks. More evidence is still needed about how well it works in the long term.

A recent study reports on long-term follow-up for 16 patients who had SABR for their primary tumour.

Read more on our website here:

30/09/2026

Please help kidney cancer patients, the IKCC patient survey is now open.
By taking 15minutes to complete the survey, your experiences will help shape kidney cancer care for the next decade.
To find out more and complete the survey please follow the link below:
https://actionkidneycancer.org/get-involved/the-5th-ikcc-global-patient-survey-on-kidney-cancer/

29/09/2026

If you or a family member have been diagnosed with kidney cancer our Patient support forum is a place where you can share your experience and concerns with other patients, carers and family members who understand the emotional and physical effects of kidney cancer.

Every member of our Patient support forum has had their life touched by kidney cancer and knows the worry and fear that a diagnosis brings with it.

We believe passionately that by sharing our experiences and offering mutual support to each other, we can help to make this awful disease a little more bearable.

To find out more and join our Patient support forum please follow the link below:

https://actionkidneycancer.org/hel.../patient-support-forum/

28/09/2026

If you are looking for a challenge in 2026 and would like to raise some funds for us there is still time to book an Ultra Challenge event.
Or would like to set yourself a goal for 2027, if so there is still time to benefit from the Ultra Challenge early bird deal which includes:
* 3 New events
* Sign up for just £5
* Free tech T shirt
* Free Virtual challenge
* Multi deal split payments

This deal closes on the 30th September 2026, why not get ahead of the crowd and book your challenge now?

To do so please follow the link below for all relevant information:

https://actionkidneycancer.org/.../ultra-challenge.../ #

The 2027 Ultra Challenge Series is open for registrations, and hundreds of keen fundraisers are thinking of their next big fundraising challenge. Are you a keen walker or runner looking for a real challenge? Perhaps you want to get in shape, to re-energise, or to fundraise for Action Kidney Cancer?....

28/09/2026

The US Food and Drug Administration (FDA) has approved the medicines belzutifan and lenvatinib to be used together for some patients with advanced clear cell renal cell carcinoma (ccRCC), a type of kidney cancer. This treatment is for patients whose cancer has already been treated with an immunotherapy.

This treatment combination (belzutifan plus lenvatinib) is not currently available on the NHS for kidney cancer. The appraisal of this combination is expected to start mid 2027, after which the decision about whether it can be used on the NHS will be made by the end of 2027.

Read more on our website here:

24/09/2026

This week, our colleague Steve Pointon Counselling and Support released the latest episode of the Living with and beyond Cancer podcast.
This weeks guest is Jemma Falloon, who was diagnosed with Kidney Cancer & Thyroid Cancer on the same day.
Please listen to Jemma's story and how she has used her experience to help other patients.

https://actionkidneycancer.org/help-support/patient-videos-and-podcasts/

24/09/2026

The 5th IKCC Global Patient Survey on Kidney Cancer is now open!
This marks 10 years of collecting data specific to the experiences of people living with kidney cancer.
The information provided allows us to track positive and negative trends, demonstrate changes over time, and use patient insights to guide future advocacy, education, and support programmes.
This survey is a landmark opportunity to help define kidney cancer care for current and future patients and is open to anyone who has lived experience with kidney cancer, whether they have received the diagnosis or are a carer to someone who has.
Your lived experience matters, please share your voice take the 15minute survey and help shape the future of kidney cancer care.

For more information and to take the survey please follow the link below:
https://actionkidneycancer.org/get-involved/the-5th-ikcc-global-patient-survey-on-kidney-cancer/